The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/show/NCT03783442




Registration number
NCT03783442
Ethics application status
Date submitted
18/12/2018
Date registered
19/12/2018
Date last updated
1/02/2019

Titles & IDs
Public title
A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as First Line Treatment in Patients With Advanced Esophageal Squamous Cell Carcinoma
Scientific title
A Randomized, Placebo-Controlled, Double-Blind Phase 3 Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma
Secondary ID [1] 0 0
2018-000587-28
Secondary ID [2] 0 0
BGB-A317-306
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Esophageal Squamous Cell Carcinoma (ESCC) 0 0
Condition category
Condition code
Cancer 0 0 0 0
Non melanoma skin cancer
Cancer 0 0 0 0
Kidney
Cancer 0 0 0 0
Oesophageal (gullet)

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Platinum (cisplatin or oxaliplatin) + Fluorouracil (5-FU)
Treatment: Drugs - Platinum (cisplatin or oxaliplatin) + capecitabine
Treatment: Drugs - Platinum (cisplatin or oxaliplatin) + paclitaxel

Experimental: Arm A - Tislelizumab + chemotherapy

Active Comparator: Arm B - Placebo + chemotherapy


Treatment: Drugs: Platinum (cisplatin or oxaliplatin) + Fluorouracil (5-FU)
Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 Q3W
5-FU 750 to 800 mg/m2 IV continuous infusion over 24 hours daily on Days 1 to 5 Q3W

Treatment: Drugs: Platinum (cisplatin or oxaliplatin) + capecitabine
Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 Q3W
Capecitabine 1000 mg/m2 orally (PO) twice daily (BID) on Days 1 to 14 Q3W

Treatment: Drugs: Platinum (cisplatin or oxaliplatin) + paclitaxel
Cisplatin 60 to 80 mg/m2 OR oxaliplatin 130 mg/m2 IV on Day 1 or 2 Q3W
Depending on local guidelines, cisplatin may be given in 3 divided doses on Days 1, 2, and 3. The total dose given must be between 60 to 80 mg/m2 per cycle.
Paclitaxel 175 mg/m2 IV on Day 1 Q3W

Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
PFS - defined as the time from the date of randomization to the date of first documentation of disease progression assessed by BIRC per RECIST v1.1 or death, whichever occurs first
Timepoint [1] 0 0
Approximately 31 months from date of the first patient randomization
Primary outcome [2] 0 0
OS - defined as the time from the date of randomization until the date of death due to any cause
Timepoint [2] 0 0
Approximately 31 months from date of the first patient randomization

Eligibility
Key inclusion criteria
Patients with unresectable, locally advanced recurrent or metastatic ESCC who have Stage IV
unresectable ESCC at first diagnosis (ie, Stage IV disease at the original diagnosis of
ESCC) or who have unresectable, locally advanced recurrent or metastatic disease with at
least a 6-month treatment-free interval, if prior definitive therapy (chemotherapy,
chemo-radiation therapy or surgery) was given.



1. Pathologically (histologically) confirmed diagnosis of ESCC

2. Stage IV unresectable ESCC at first diagnosis OR unresectable, locally advanced
recurrent or metastatic disease with a treatment free interval of at least 6 months
after definitive treatment.
Minimum age
18 Years
Maximum age
No limit
Gender
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. Palliative radiation treatment for ESCC within 4 weeks of study treatment initiation

2. Prior systemic therapy for unresectable, locally advanced recurrent or metastatic ESCC

3. Received prior therapies targeting PD-1, PD-L1 or PD-L2

4. Patients with evidence of fistula (either esophageal/bronchial or esophageal/aorta)

5. Uncontrollable pleural effusion, pericardial effusion, or ascites requiring frequent
drainage or medical intervention (clinically significant recurrence requiring an
additional intervention within 2 weeks of intervention)

6. Evidence of complete esophageal obstruction not amenable to treatment

7. Unintentional weight loss = 5% within one month prior to randomization or other
indicators of severe malnutrition (Severe malnutrition may be determined using the
Nutritional Risk Index (Shirasu, et al. 2018))

8. Patients receiving chemotherapy doublet C (platinum and paclitaxel) must not have
peripheral neuropathy = Grade 2 at baseline

9. Patients who recur after definitive surgery and are eligible for non-palliative
radiation therapy and/or chemoradiotherapy.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint(s)
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
Sample size
Target
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
VIC,WA
Recruitment hospital [1] 0 0
Ballarat Oncology & Haematology Services - Wendouree
Recruitment hospital [2] 0 0
St John of God Health Care - Subiaco
Recruitment postcode(s) [1] 0 0
3355 - Wendouree
Recruitment postcode(s) [2] 0 0
6008 - Subiaco
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Texas
Country [2] 0 0
Belgium
State/province [2] 0 0
Antwerpen
Country [3] 0 0
Belgium
State/province [3] 0 0
Hainaut
Country [4] 0 0
Belgium
State/province [4] 0 0
Oost-Vlaanderen
Country [5] 0 0
Belgium
State/province [5] 0 0
Vlaams Brabant
Country [6] 0 0
Belgium
State/province [6] 0 0
West-Vlaanderen
Country [7] 0 0
Belgium
State/province [7] 0 0
Liège
Country [8] 0 0
China
State/province [8] 0 0
Anhui
Country [9] 0 0
China
State/province [9] 0 0
Beijing
Country [10] 0 0
China
State/province [10] 0 0
Fujian
Country [11] 0 0
China
State/province [11] 0 0
Guangdong
Country [12] 0 0
China
State/province [12] 0 0
Guangxi
Country [13] 0 0
China
State/province [13] 0 0
Guangzhou
Country [14] 0 0
China
State/province [14] 0 0
Hainan
Country [15] 0 0
China
State/province [15] 0 0
Heilongjiang
Country [16] 0 0
China
State/province [16] 0 0
Henan
Country [17] 0 0
China
State/province [17] 0 0
Hubei
Country [18] 0 0
China
State/province [18] 0 0
Hunan
Country [19] 0 0
China
State/province [19] 0 0
Jiangsu
Country [20] 0 0
China
State/province [20] 0 0
Jiangxi
Country [21] 0 0
China
State/province [21] 0 0
Liaoning
Country [22] 0 0
China
State/province [22] 0 0
Shandong
Country [23] 0 0
China
State/province [23] 0 0
Shanghai
Country [24] 0 0
China
State/province [24] 0 0
Shanxi
Country [25] 0 0
China
State/province [25] 0 0
Tianjin
Country [26] 0 0
China
State/province [26] 0 0
Zhejiang
Country [27] 0 0
Czechia
State/province [27] 0 0
Olomouc
Country [28] 0 0
France
State/province [28] 0 0
Bretagne
Country [29] 0 0
France
State/province [29] 0 0
Franche-Comté
Country [30] 0 0
France
State/province [30] 0 0
Vienne
Country [31] 0 0
Germany
State/province [31] 0 0
Hamburg
Country [32] 0 0
Italy
State/province [32] 0 0
Forli
Country [33] 0 0
Japan
State/province [33] 0 0
Hirosima [Hiroshima]
Country [34] 0 0
Japan
State/province [34] 0 0
Kumamoto
Country [35] 0 0
Japan
State/province [35] 0 0
Saitama
Country [36] 0 0
Japan
State/province [36] 0 0
Akita-shi
Country [37] 0 0
Japan
State/province [37] 0 0
Osaka
Country [38] 0 0
Japan
State/province [38] 0 0
Ôsaka [Osaka]
Country [39] 0 0
Korea, Republic of
State/province [39] 0 0
Daegu Gwang'yeogsi [Taegu-Kwan
Country [40] 0 0
Korea, Republic of
State/province [40] 0 0
Gyeonggido [Kyonggi-do]
Country [41] 0 0
Korea, Republic of
State/province [41] 0 0
Jeonranamdo [Chollanam-do]
Country [42] 0 0
Korea, Republic of
State/province [42] 0 0
Seoul Teugbyeolsi [Seoul-T'ukp
Country [43] 0 0
Korea, Republic of
State/province [43] 0 0
Seoul
Country [44] 0 0
Poland
State/province [44] 0 0
Mazowieckie
Country [45] 0 0
Poland
State/province [45] 0 0
Podkarpackie
Country [46] 0 0
Poland
State/province [46] 0 0
Poznan
Country [47] 0 0
Romania
State/province [47] 0 0
Cluj
Country [48] 0 0
Romania
State/province [48] 0 0
Dolj
Country [49] 0 0
Russian Federation
State/province [49] 0 0
Arkhangelsk
Country [50] 0 0
Spain
State/province [50] 0 0
Barcelona
Country [51] 0 0
Spain
State/province [51] 0 0
Madrid
Country [52] 0 0
Spain
State/province [52] 0 0
Zaragoza
Country [53] 0 0
Taiwan
State/province [53] 0 0
Kaohsiung
Country [54] 0 0
United Kingdom
State/province [54] 0 0
York

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
BeiGene
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to evaluate the efficacy and safety of Tislelizumab as first
line treatment in combination with chemotherapy in patients with advanced
unresectable/metastatic ESCC.
Trial website
https://clinicaltrials.gov/show/NCT03783442
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Virginia Paton, Europe and United States
Address 0 0
Country 0 0
Phone 0 0
1 (877) 828-5568
Fax 0 0
Email 0 0
clinicaltrials@beigene.com
Contact person for scientific queries

No data has been provided for results reporting
Summary results
Not applicable